利生奇珠单抗

{{Infobox drug
| type = mab
| image =
| alt =
| caption =

| mab_type = mab
| source = zu
| target = interleukin 23A

| pronounce =

| tradename = Skyrizi
| Drugs.com =
| MedlinePlus = a619035
| DailyMedID = Risankizumab
| pregnancy_AU = B1
| pregnancy_AU_comment =
| pregnancy_category=
| routes_of_administration = 皮下注射
| class =
| ATC_prefix = L04
| ATC_suffix = AC18
| ATC_supplemental =

| legal_AU = S4
| legal_AU_comment =
| legal_BR =
| legal_BR_comment =
| legal_CA = Rx-only
| legal_CA_comment = / Schedule D
| legal_DE =
| legal_DE_comment =
| legal_NZ =
| legal_NZ_comment =
| legal_UK = POM
| legal_UK_comment =
| legal_US = Rx-only
| legal_US_comment =
| legal_EU = Rx-only
| legal_EU_comment =
| legal_UN =
| legal_UN_comment =
| legal_status = Rx-only。它可以结合并阻断（IL-23A）。

最常见的副作用包括上呼吸道感染（鼻咽感染） ，此外全球包括欧盟 和台灣皆可獲得醫療使用許可。

參考文獻
外部連節
*
*
*
*
*